97774125 - MYHAEVYN

Information

• Trademark
• 97774125

• Source

• Serial Number

  97774125

• International Classifications

  • 5 - Pharmaceutical and veterinary preparations

• Filing Date

  January 31, 2023
  a year ago

• Transaction Date

  June 21, 2023
  a year ago

• Status Date

  June 21, 2023
  a year ago

• Location Date

  February 17, 2023
  a year ago

• Status Code

  601

• Current Location

  NEW APPLICATION PROCESSING

• Attorney Docket Number

  034845.361

  Attorney Name

  Scott D. Woldow

• Owners

  • CSL BEHRING AG

Case File Statements

• GS0051: Pharmaceutical preparations for treating von Willebrand disease, hemophilia, primary immunodeficiency, hereditary angioedema, fibrinogen deficiency, Alpha 1 antitrypsin deficiency, and inflammatory demyelinating polyneuropathy; blood plasma; blood plasma fractions; recombinant protein arrays for medical diagnosis purposes; Pharmaceutical preparations for the treatment and prevention of blood and bleeding disorders; blood products for the treatment of hemophilia, namely, pharmaceutical preparations for the treatment of hemophilia; pharmaceutical products derived from recombinant DNA technology for the treatment of hemophilia, namely, pharmaceutical preparations derived from recombinant DNA technology for the treatment of hemophilia; blood products for the treatment of hemophilia, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; pharmaceutical preparations and substances for the treatment of blood disorders; antibodies, namely, diagnostic kits consisting primarily of monoclonal antibodies, buffers, and reagents for use in disease testing; blood for medical purposes; cell cultures for medical purposes, namely, cells for medical or clinical use; cell cultures for medical purposes, namely, living cells for medical use; cell cultures for medical purposes, namely, stem cells for medical or veterinary use; pharmaceutical preparations for the treatment of blood conditions, respiratory conditions, pneumonia, covid-19, and influenza; Pharmaceutical preparations, namely, antibody for the treatment of acute respiratory distress syndrome, ARDS; pharmaceutical preparations, namely, antibody for the treatment of Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; Pharmaceutical preparations, namely, antibody for the treatment of Hereditary Angioedema, HAE; Pharmaceutical preparations, namely, for the treatment of Hereditary Angioedema, HAE, respiratory diseases, acute respiratory distress syndrome, ARDS, Idiopathic Pulmonary Fibrosis, IPF and Interstitial Lung Diseases, ILD; antibodies

Case File Event Statements

• 6/21/2023 - a year ago

  5 - ABANDONMENT NOTICE E-MAILED - EXPRESS ABANDONMENT Type: MAB1

• 6/21/2023 - a year ago

  4 - ABANDONMENT - EXPRESS MAILED Type: ABN1

• 6/20/2023 - a year ago

  3 - TEAS EXPRESS ABANDONMENT RECEIVED Type: EXAR

• 2/17/2023 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 2/3/2023 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP